{"filings":[{"id":2244319,"accession_number":"0001104659-26-095925","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K/A","filed_at":"2026-08-13T20:14:54+00:00","items":["2.02","9.01","7.01"],"status":"ready","headline":"Yarrow (fka VYNE) closes reverse merger with YB-101 developer; $100M cash, $71M net loss","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed July 27, 2026: VYNE issued 2,130,731 shares at 0.7171 exchange ratio; 25.6M pre-funded warrants and 2.0M options converted.","Pre-Merger Yarrow raised $99.85M net via 14,516,188 Series A preferred shares at $6.89/share; cash of $99.99M at Dec 31, 2025.","Net loss of $70.99M from Oct 3, 2025 inception to Dec 31, 2025, including $70M acquired in-process R&D (upfront license fee to GenSci).","Lead asset YB-101 (anti-TSHR antibody for Graves' disease) received FDA IND clearance March 2026; Phase 2a/2b trial expected H1 2026.","Cash of $30M remains after $70M license fee; management says sufficient for 12+ months of operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1967636,"accession_number":"0001104659-26-088662","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2026-07-30T20:03:20+00:00","items":["8.01"],"status":"ready","headline":"Yarrow Bioscience exchanges shares for pre-funded warrants; warrant count dwarfs common shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged 133,290 common shares for pre-funded warrants to purchase same number at $0.0001/share.","After exchange: 2,669,788 common shares outstanding; 25,914,530 pre-funded warrants outstanding.","Warrants immediately exercisable, subject to 9.99% beneficial ownership limitation (can be increased to 19.99%).","Exchange closed July 29, 2026; issued under Section 3(a)(9) exemption from registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1915680,"accession_number":"0001104659-26-087601","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2026-07-28T21:11:31+00:00","items":["1.01","2.01","2.02","3.02","3.03","5.01","5.02","5.03","5.05","7.01","9.01"],"status":"ready","headline":"Yarrow Bioscience completes reverse merger with VYNE; Yarrow stockholders own 97% of combined company","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["VYNE valued at $8.5M, Pre-Merger Yarrow at $272.9M; exchange ratio 0.7171 shares of new co per Yarrow share.","Pre-Merger Yarrow stockholders own ~97% of combined company; VYNE stockholders ~3%.","VYNE paid $17.3M cash dividend ($0.40242/share) to its stockholders prior to close.","New board and officers appointed: CEO Rebecca Frey, CFO Tyler Zeronda, and four other C-suite; board of six members.","Pre-Merger Yarrow raised $200M in total: $100M Series A preferred and $100M PIPE pre-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1757837,"accession_number":"0001104659-26-085235","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2026-07-21T12:14:41+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"VYNE announces 1-for-50 reverse stock split and $17.3M special dividend for Yarrow merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-50 reduces outstanding shares from ~33.4M to ~0.7M.","Aggregate special cash dividend of $17.3M ($0.40242/share) payable July 23 to holders of record July 22.","Merger with Yarrow Bioscience expected to close July 24; combined company to trade as YARW on Nasdaq on July 27.","Post-merger combined company shares: ~2.7M basic, ~33.6M fully diluted.","Stockholders approved reverse split and increase in authorized shares from 150M to 300M at July 16 special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1729599,"accession_number":"0001104659-26-084760","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2026-07-18T00:41:06+00:00","items":["5.07"],"status":"ready","headline":"VYNE stockholders approve all proposals for merger with Yarrow Bioscience at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1 (issuance of shares >20% and change of control) approved: 15,915,017 for, 137,159 against.","Proposal 2 (reverse stock split 1:10-70) approved: 25,389,760 for, 550,694 against.","Proposal 3 (increase authorized shares from 150M to 300M) approved: 23,921,348 for, 2,013,526 against.","Proposal 4 (Yarrow 2026 Stock Incentive Plan) approved: 12,691,384 for, 3,358,164 against.","Proposal 5 (Yarrow 2026 Employee Stock Purchase Plan) approved: 13,131,018 for, 2,909,493 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1619636,"accession_number":"0001104659-26-083356","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2026-07-14T12:12:23+00:00","items":["7.01","9.01"],"status":"ready","headline":"Yarrow Bioscience publishes investor presentation; VYNE makes available on website","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Yarrow Bioscience published an investor presentation dated July 14, 2026, which VYNE made available on its website.","The presentation is related to the proposed transaction between VYNE and Yarrow, as referenced in the S-4 registration statement.","No specific financial or operational details from the presentation are included in the filing text provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1563116,"accession_number":"0001104659-26-082433","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2026-07-10T12:06:31+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"VYNE declares special cash dividend of $0.38/share in connection with Yarrow merger","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Estimated aggregate $16.5M special cash dividend ($0.38/share) declared; record date July 22, 2026.","Dividend conditioned on closing of merger with Yarrow Bioscience; expected close on/about July 24, 2026.","Stockholder vote on merger scheduled for July 16, 2026; dividend payable after close.","Per-share amount based on 42,989,506 shares and equivalents outstanding as of July 9, 2026.","Actual distribution may be higher or lower than estimate; payment to transfer agent on July 23, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":583958,"accession_number":"0001104659-26-065214","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2026-05-21T21:00:44+00:00","items":["7.01","9.01"],"status":"ready","headline":"VYNE and Yarrow publish investor presentation for proposed merger","summary_kind":"llm","event_type":"m_and_a","confidence":"low","bullets":["Yarrow Bioscience published an investor presentation on May 21, 2026, now available on VYNE's website.","VYNE previously filed Form S-4 (No. 333-294804) with proxy statement/prospectus for the proposed Yarrow acquisition.","Presentation provides overview of Yarrow's business as part of the pending merger with VYNE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105566,"accession_number":"0001104659-26-026439","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"VYNE receives Nasdaq extension to Sept 7, 2026 to regain $1 bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company failed to regain minimum $1.00 bid price by original March 10, 2026 deadline.","Nasdaq granted additional 180 calendar days, until September 7, 2026, to cure deficiency.","VYNE may consider a reverse stock split to meet the bid price requirement.","Common stock continues trading on Nasdaq Capital Market under symbol VYNE during extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105565,"accession_number":"0001104659-26-008642","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"VYNE amends merger with Yarrow to allow pre-funded warrants and beneficial ownership cap","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amendment allows pre-funded warrants for Yarrow stockholders exceeding 9.99% beneficial ownership limit.","Parent Pre-Closing Dividend will also be paid to holders of VYNE warrants, per their terms.","Beneficial ownership limitation per holder set at 0%-19.99%, default 9.99%.","Amendment signed Jan 30, 2026; merger originally announced Dec 17, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121847,"accession_number":"0001104659-25-121828","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["1.01","3.02","5.01","5.02","7.01","9.01"],"status":"ready","headline":"VYNE Therapeutics to merge with Yarrow Bioscience; Yarrow stockholders to own ~97% of combined company","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Pro forma ownership: pre-Merger Yarrow stockholders ~97%, VYNE stockholders ~3%.","Pre-Closing Dividend of ~$14.5M to $16.5M to VYNE stockholders prior to close.","Two concurrent financings: Yarrow Series A preferred ~$100M and Pre-Closing PIPE ~$100M.","Expected close Q2 2026; post-close board and officers designated by Yarrow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121846,"accession_number":"0001104659-25-120637","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"VYNE Therapeutics annual meeting elects directors, ratifies auditor, approves say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class I directors Elisabeth Sandoval Little and Steven Basta elected with ~3.9M votes each.","Baker Tilly US, LLP ratified as independent auditor for FY 2024 with 15.3M votes for.","Advisory vote on named executive officer compensation passed with 4.6M votes for.","Quorum of 50.1% of 33.3M shares outstanding at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121845,"accession_number":"0001566044-25-000007","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VYNE reports Q3 net loss $7.3M; cash $32.7M; strategic review ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.3M ($0.17 per share) vs $12.2M ($0.29) in Q3 2024; revenue $0.2M from Finacea royalty.","Cash, cash equivalents and marketable securities $32.7M as of Sep 30, 2025; runway into first half 2027.","FDA partial clinical hold on VYN202 for male subjects; 12-week dog tox study ongoing to resolve.","Phase 2b repibresib gel for vitiligo failed primary endpoint F-VASI50; trial being terminated.","Board initiated strategic review in Aug 2025; evaluating partnerships, M&A, asset sales; LifeSci Capital engaged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138527,"accession_number":"0001104659-25-089531","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"VYNE receives Nasdaq bid price deficiency notice; 180-day cure period to March 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price of VYNE common stock below $1.00 for 30 consecutive business days.","180-day compliance period until March 10, 2026; stock continues trading on Nasdaq Capital Market.","Compliance regained if bid price closes at $1.00+ for 10 consecutive trading days before deadline.","Company evaluating options; may seek second 180-day period if not compliant by March 10, 2026.","Failure to regain compliance could result in delisting of common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138526,"accession_number":"0001104659-25-078135","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"VYNE Q2 net loss $5.8M; cash runway extended to H1 2027; two directors resign","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $39.6M as of Jun 30, expected to fund ops into first half of 2027.","Net loss $5.8M ($0.13 per share) vs $9.4M ($0.22) in Q2 2024; revenue $0.1M from Finacea royalty.","Directors Christine Borowski and Anthony Bruno resigned effective Aug 11 and 13, 2025; no dispute with company.","Repibresib Phase 2b vitiligo trial missed primary endpoint; company seeking partner for program.","FDA lifted clinical hold on VYN202 Phase 1b for female subjects; partial hold remains for males pending new toxicology study."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":271000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138525,"accession_number":"0001104659-25-071953","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"VYNE Phase 2b Repibresib vitiligo trial misses F-VASI50, terminates extension, seeks partner","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint F-VASI50 at Week 24 not met: 19.5% for 3% vs 23.4% vehicle (p=0.1245).","Key secondary endpoint F-VASI75 also not met (9.8% vs 6.4%, p=0.1468).","Nominal statistical significance for 3% dose on percent CFB in F-VASI (-43.6% vs -25.6%, p=0.002) and T-VASI (-28.3% vs -16.2%, p=0.044).","High vehicle effect and dropout rate in active arms (36.6% for 3% vs 10.6% vehicle); company ends trial extension phase.","Preliminary cash $39.6M as of June 30, 2025; company seeking partner for Repibresib."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155983,"accession_number":"0001628280-25-023478","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VYNE Q1 net loss $8.6M; VYN202 psoriasis trial on clinical hold; repibresib vitiligo data due mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $50.3M; net loss $8.6M ($0.20/sh) vs $6.2M in Q1 2024.","R&D expenses $6.1M, up from $3.7M, driven by VYN202 and repibresib trials.","Phase 1b psoriasis trial of VYN202 placed on clinical hold after testicular toxicity in dogs.","Repibresib gel Phase 2b vitiligo top-line results expected mid-2025; fully enrolled.","Revenue $0.2M from LEO Pharma royalty; cash runway into 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":202000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174446,"accession_number":"0001628280-25-010777","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VYNE reports FY2024 net loss $39.8M; cash $61.5M; repibresib Phase 2b data due mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash & equivalents total $61.5M as of Dec 31, 2024; expected runway into 2H 2026.","Net loss for FY 2024 was $39.8M ($0.93 per share) vs $28.5M ($2.78 per share) in 2023.","R&D expenses doubled to $30.9M driven by Phase 2b repibresib and Phase 1a VYN202 trials.","Repibresib gel Phase 2b vitiligo top-line data expected mid-2025; fully enrolled ~180 subjects.","VYN202 Phase 1b psoriasis trial initiated; top-line results expected by year-end 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174445,"accession_number":"0001104659-25-002862","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"VYNE updates corporate presentation with previously announced Phase 1a data for VYN202","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Phase 1a data for VYN202 and pipeline program updates included in presentation; data was previously announced.","Presentation posted on company website and filed as Exhibit 99.1 on January 13, 2025.","No new financial results or material events disclosed in this 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191403,"accession_number":"0001104659-24-131064","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"VYNE reports positive Phase 1a MAD data for VYN202; no AE, robust biomarker activity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VYN202 showed favorable safety with no drug-related AEs, including no thrombocytopenia or neutropenia.","PK supports once-daily dosing; dose-dependent exposure reached steady-state after 7 days.","Increased target engagement biomarker HEXIM-1; inhibited Th17, Th1/myeloid, Th1/Tc inflammatory biomarkers.","No drug-drug interaction when co-administered with methotrexate, a common treatment for immune conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191402,"accession_number":"0001104659-24-127997","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve 1.52M share increase in 2023 Equity Incentive Plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increase of 1,520,000 shares to 2023 Plan; total reserve now 1,651,907 shares.","Eliminated 'liberal' share recycling for stock options and SARs.","Incentive stock option limit raised to 3,619,586 shares.","David Domzalski and Patrick LePore re-elected as Class III directors.","Baker Tilly ratified as auditor; say-on-pay approved; advisory vote set for every year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191401,"accession_number":"0001628280-24-045998","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VYNE reports Q3 net loss $12.2M; VYN201 Phase 2b enrollment exceeds target, top-line mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.2M ($0.29/sh) in Q3 2024 vs $6.6M ($2.01/sh) in Q3 2023, driven by higher R&D spend.","Cash and marketable securities of $70.2M; expected to fund operations through end of 2025.","VYN201 Phase 2b vitiligo trial enrollment exceeded target; fully enrolled Dec 2024, top-line mid-2025.","VYN202 Phase 1a SAD data positive; MAD data expected Q4 2024. Plans for Phase 1b in psoriasis and RA.","R&D expenses rose 208.9% to $10.2M due to advancing clinical trials."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":417000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207887,"accession_number":"0001104659-24-099121","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"VYNE Therapeutics reports positive Phase 1a SAD data for VYN202; no drug-related adverse events","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VYN202 well tolerated across all dose groups; no serious or drug-related AEs, no clinically significant lab/ECG abnormalities.","PK results showed dose-dependent exposure of VYN202 in plasma and urine across all doses tested.","PD activity observed: increased HEXIM1 (target engagement) and inhibitory effect on inflammatory biomarkers for psoriasis and rheumatoid arthritis.","Dosing in the multiple ascending dose (MAD) portion of Phase 1a has begun; results expected Q4 2024.","CEO David Domzalski highlighted milestone for the company's BD2-selective BET inhibitor platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207886,"accession_number":"0001628280-24-037051","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VYNE Therapeutics Q2 2024 net loss $9.4M; cash $78.1M funds milestones into 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.4M ($0.22 EPS) vs $10.1M ($3.09 EPS) in Q2 2023.","Cash, cash equivalents, restricted cash and marketable securities of $78.1M as of June 30, 2024.","Initiated Phase 2b trial of VYN201 in nonsegmental vitiligo; top-line results expected mid-2025.","Phase 1a SAD/MAD trial of VYN202 ongoing; SAD data in Q3 2024, MAD data in Q4 2024.","Appointed Dr. Subhashis Banerjee as SVP of Clinical Development; previously at Bristol Myers Squibb."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":296000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225357,"accession_number":"0001628280-24-021971","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VYNE reports Q1 2024 net loss of $6.2M, cash $86M; vitiligo Phase 2b trial on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, restricted cash and marketable securities of $86.0M as of March 31; runway through end of 2025.","Net loss $6.2M ($0.15/sh) vs $5.6M ($1.74/sh) in Q1 2023; R&D expense up 35.6% to $3.7M.","Phase 2b trial for VYN201 in nonsegmental vitiligo to enroll ~160 subjects in 1%,2%,3% gel vs vehicle; first dose expected Q2 2024.","IND cleared for oral BET inhibitor VYN202; Phase 1a SAD/MAD starting Q2 2024 with top-line data H2 2024.","Top-line Phase 2b data expected mid-2025; Phase 1b trials in psoriasis and RA planned for H2 2025 if Phase 1a successful."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":98000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244567,"accession_number":"0001104659-24-029097","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VYNE reports Q4/FY 2023 loss; cash $93.3M; VYN201 Phase 2b starts Q2 2024; VYN202 Phase 1a expected Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, restricted cash and marketable securities $93.3M at Dec 31, 2023, providing runway through end of 2025.","GAAP loss from continuing ops Q4 2023 $6.15M vs $7.76M in Q4 2022; full year $27.87M vs $33.95M (improved YoY).","Adjusted net loss Q4 2023 $5.48M vs $8.88M; full year $25.15M vs $18.91M (wider YoY for FY).","VYN201 Phase 2b trial in nonsegmental vitiligo to begin Q2 2024; top-line results mid-2025; gel formulation selected.","VYN202 IND submitted Dec 2023; FDA requested additional nonclinical study; completed consistent with expectations; Phase 1a expected Q2 2024 if FDA clears."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":424000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244566,"accession_number":"0001104659-24-000584","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2024-01-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"VYNE Therapeutics appoints Christine Borowski, Ph.D., to board of directors effective Jan 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Dr. Christine Borowski as Class II director, effective Jan 1, 2024, for term until 2026 annual meeting.","Dr. Borowski is Vice President at Access Bio and was appointed per prior agreement from Nov 2023 private placement.","Received option to purchase 40,000 shares at $2.33/share, vesting annually over 3 years.","Will receive standard annual cash retainer of $40,000, payable quarterly, plus annual option awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261998,"accession_number":"0001104659-23-125694","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2023-12-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"VYNE shareholders approve 2023 Equity Incentive Plan; CEO granted 225K RSUs and options","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 2023 Equity Incentive Plan authorizing 2,099,856 shares, effective Dec 13, 2023.","CEO David Domzalski receives 225,000 RSUs and options for 225,000 shares on Dec 13, 2023, and another 225,000 RSUs and options on Jan 1, 2024.","Each of three other named executives (Harsch, Stuart, Zeronda) gets 62,500 RSUs and 62,500 options on both Dec 13 and Jan 1.","Annual meeting results: Sharon Barbari elected director; Baker Tilly ratified as auditor for FY2023.","Equity awards vest over four years; option exercise price equals closing price on grant date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261997,"accession_number":"0001104659-23-116712","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VYNE raises $88.2M, reports positive Phase 1b vitiligo data for VYN201","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$88.2M private placement closed Nov 1; cash runway extended through end of 2025.","Phase 1b: VYN201 mean F-VASI reduction 30.2% (1%) and 39.0% (2%) at 16 weeks; well-tolerated.","Phase 2b trial for VYN201 in vitiligo expected H1 2024; top-line results mid-2025.","VYN202 IND submission by year-end 2023; Phase 1a trial in Q1 2024; Phase 1b in psoriasis/RA H2 2024.","Q3 2023 GAAP net loss $6.6M, adjusted net loss $5.7M; cash runway through 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261996,"accession_number":"0001104659-23-112359","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["1.01","1.02","2.02","3.02","5.08","7.01","8.01","9.01"],"status":"ready","headline":"VYNE announces $88M PIPE funding and positive clinical data for VYN201 and VYN202","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $88M gross from PIPE led by Access Biotechnology, with participation from healthcare investors.","Phase 1b VYN201 vitiligo trial: 1.0% cohort 30.3% mean F-VASI reduction (p=0.0137), 2.0% cohort 39.0% (p=0.0077) vs 0.5%.","VYN202 preclinical: 95% PASI reduction in psoriasis model; 71% reduction in rheumatoid arthritis signs/symptoms.","Preliminary cash $15.5M as of Sep 30, 2023; with PIPE proceeds pro forma $103.7M.","Next steps: Phase 2b VYN201 in vitiligo in 1H2024; Phase 1a VYN202 trial expected Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279189,"accession_number":"0001628280-23-029193","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VYNE Therapeutics Q2 net loss $10.1M; VYN201 phase 1b data due Q3 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.1M ($3.09 per share) vs $8.5M ($2.63) in Q2 2022; revenue flat at $0.1M.","Cash and restricted cash $20.7M as of June 30, 2023; expects to fund operations through end of 2023.","R&D expenses rose to $7.2M from $4.1M YoY, primarily due to VYN202 license payment and development costs.","VYN201 Phase 1b preliminary safety/efficacy data in nonsegmental vitiligo anticipated in Q3 2023.","VYN202 IND submission expected by year-end; Phase 1 trial to begin Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":234000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297523,"accession_number":"0001628280-23-017579","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VYNE Therapeutics reports Q1 2023 net loss of $5.6M; VYN201 Phase 1b data expected Q3 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2023 GAAP net loss $5.6M vs net income $4.7M in Q1 2022; loss from continuing ops improved to $5.6M from $8.7M.","Topline 16-week data for all three cohorts of VYN201 Phase 1b trial in vitiligo expected in Q3 2023.","Lead development candidate selected for VYN202 oral BD2-selective BET inhibitor; IND filing targeted by year-end 2023.","Positive safety and PK data from VYN201 Phase 1a; no serious adverse events or dose adjustments.","Preclinical data for inhaled VYN201 in IPF model showed anti-inflammatory and anti-fibrotic effects."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":99000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297522,"accession_number":"0001104659-23-053593","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"VYNE Therapeutics licenses BD2-selective BET inhibitors, selects development candidate VYN202","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$3.75M upfront payment for exclusive worldwide license; up to $68.75M in milestones plus tiered royalties.","VYN202 is oral BD2-selective BET inhibitor for immuno-inflammatory conditions; IND-enabling studies ongoing.","Preclinical data suggests VYN202 may be best-in-class with potent anti-inflammatory and anti-fibrotic effects.","IND filing planned by year-end; VYNE expects to advance VYN202 into clinical development.","VYNE also obtained rights to additional BD2-selective BET inhibitor compounds from Tay Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317830,"accession_number":"0001628280-23-007294","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VYNE reports FY2022 net loss $23.2M; VYN201 Phase 1b in vitiligo dosing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss of $23.2M for FY2022 vs $73.3M in 2021; adjusted net loss $18.9M.","Topline Phase 1b data for VYN201 (pan-BD BET inhibitor) in vitiligo expected mid-2023.","Positive preliminary Phase 1a safety data for VYN201; three doses selected for Phase 1b.","Regained Nasdaq minimum bid price compliance after 1-for-18 reverse stock split in Feb 2023.","VYN202 option agreement extended to April 2023; IND-enabling studies planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317829,"accession_number":"0001104659-23-026761","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"VYNE extends Oral BETi option to April 30, 2023; regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extended option term for Oral BETi Compounds to April 30, 2023; paid Tay $250k non-refundable fee.","Fee will be deducted from $4.0M upfront if option exercised.","Received Nasdaq notice on Feb 28, 2023 that bid price ≥$1.00 for 10 consecutive business days through Feb 27, 2023.","Regained compliance with Nasdaq Rule 5550(a)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317828,"accession_number":"0001104659-23-018639","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2023-02-10T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"VYNE Therapeutics completes 1:18 reverse stock split, reducing shares to ~3.25M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1:18 reverse stock split effective Feb 10, 2023; shares outstanding drop from 58.5M to ~3.25M.","Board approved final ratio on Feb 8; stockholders authorized range 1:10–1:25 at Jan 12 special meeting.","No fractional shares issued; cash payments in lieu. Trading on split-adjusted basis begins Feb 13, 2023.","CUSIP changes to 92941V 308; all stock options and warrants adjusted proportionally with higher exercise price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317827,"accession_number":"0001104659-23-004316","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2023-01-17T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"VYNE redeems all Series A Preferred Stock for $360K, eliminates series designation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Redeemed all outstanding Series A Convertible Preferred Stock for $360,000 (120% of stated value) on Jan 17, 2023.","Filed Certificate of Elimination removing designation of 3,000 Series A shares with Delaware Secretary of State.","Eliminated shares resume status as authorized but unissued and non-designated preferred stock.","No outstanding Series A shares remain after redemption; sole holder received full payment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317826,"accession_number":"0001104659-23-003471","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2023-01-12T23:59:59+00:00","items":["2.02","8.01","5.07","7.01"],"status":"ready","headline":"VYNE shareholders approve reverse stock split; receives $5M deferred payment; redeems preferred","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse stock split at ratio from 1:10 to 1:25; board to set effective date within one year.","Series A Preferred redeemed for $360,000 on Jan 17, 2023; Certificate of Elimination to be filed.","Received $5.0M deferred payment from Journey Medical per Asset Purchase Agreement; pro forma cash $35.9M as of Dec 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336087,"accession_number":"0001104659-22-117150","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"VYNE Q3 net loss $9.5M; VYN201 Phase 1a/b enrollment imminent; FMX114 strategy under review","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2022 net loss $9.5M vs $21.3M; operating loss $9.3M vs $14.3M year-over-year.","IND cleared for VYN201; first patient expected in Phase 1a/b vitiligo trial Nov. 2022 with topline data H1 2023.","FMX114 Phase 2a missed primary endpoint at week 4 but statistically superior at weeks 1-3; evaluating strategy for moderate-to-severe AD.","VYN202 oral BETi program progressing with Tay Therapeutics toward lead candidate selection.","Corporate presentation posted; cash position not separately disclosed in released results."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":471000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353531,"accession_number":"0001104659-22-096092","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2022-08-30T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"VYNE receives Nasdaq extension to Feb 2023; pays Tay £850k for BETi compounds","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted 180-day extension until Feb 27, 2023 to regain minimum $1.00 bid price for 10 consecutive days.","VYNE common stock transferred from Nasdaq Global Select to Capital Market, effective Aug 31, 2022.","VYNE paid Tay Therapeutics £850,000 after receipt of Oral BETi Compounds meeting specified molecular profile.","Company expects to exercise exclusive option on Oral BETi Compounds by end of 2022, before Feb 28, 2023 expiry.","If compliance not regained by Feb 27, 2023, Nasdaq will delist; VYNE may appeal or consider reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353530,"accession_number":"0001628280-22-022587","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2022-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VYNE Therapeutics Q2 2022 net loss $8.5M, improved from $19.9M YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP loss from continuing operations $8.2M in Q2 2022 vs $10.7M in Q2 2021.","Adjusted net loss (non-GAAP) $7.3M in Q2 2022 vs $18.0M in prior year.","Six-month adjusted net loss $1.8M vs $36.1M in H1 2021, driven by discontinued operations.","CEO highlights BET inhibitor platform potential for immuno-inflammatory diseases.","No revenue reported; company remains in development stage."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":304000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353529,"accession_number":"0001104659-22-088684","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"VYNE's FMX114 Phase 2a AD trial misses primary endpoint; shareholders reject reverse stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2a trial of FMX114 for mild-to-moderate atopic dermatitis did not meet primary endpoint (ADSI change at week 4, p=0.228).","Mean ADSI reduction -60.62% for FMX114 vs -51.32% for vehicle; not statistically significant.","CEO disappointed; company will evaluate pipeline and prioritization.","Cash ~$43M as of June 30, 2022; $5M payment due Jan 2023 from MST franchise sale.","Shareholders voted against reverse stock split (needed >28.9M votes, got 23.7M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353528,"accession_number":"0001104659-22-082999","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2022-07-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"VYNE CSO presents InhiBET platform at B&T Cell-Mediated Autoimmune Conference","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["CSO Iain Stuart, Ph.D., presented at B&T Cell-Mediated Autoimmune Disease Drug Development Conference on July 27, 2022.","Presentation covered the InhiBET platform for bromodomain & end terminal (BET) inhibitors in autoimmune disease.","No new clinical data, financial results, or guidance changes disclosed in the filing or presentation exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371236,"accession_number":"0001104659-22-072157","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2022-06-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"VYNE completes Phase 2a enrollment for FMX114; extends In4Derm Oral BETi option to Feb 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment completed in Phase 2a trial of FMX114 for mild-to-moderate atopic dermatitis; top-line results expected in 6-8 weeks.","Option term for Oral BETi Compounds extended to Feb 28, 2023; VYNE to pay In4Derm £300,000 by June 30, 2022.","Upon discovery of two Oral BETi Compounds with specified molecular profile, VYNE to pay In4Derm additional £850,000.","Previous Phase 1b segment showed statistically significant reduction in ADSI score and pruritus with FMX114 vs vehicle."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371235,"accession_number":"0001104659-22-061796","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2022-05-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"VYNE hosts KOL event to update on BET inhibitor platform and VYN201","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Virtual KOL event held May 17, 2022 on InhiBET platform and VYN201.","Presentation attached as Exhibit 99.1 and available on company website.","No specific clinical data or financial results disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371234,"accession_number":"0001104659-22-059435","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VYNE Q1 continuing ops loss $8.7M; divested MST franchise for $25M; positive FMX114 Phase 1b data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2022 GAAP loss from continuing ops $8.7M ($7.4M adjusted); net income $4.7M reflecting divestiture gain.","Divested MST franchise (AMZEEQ, ZILXI) to Journey Medical for $25M upfront plus up to $450M milestones.","FMX114 Phase 1b showed stat sig reduction in ADSI score vs vehicle; Phase 2a topline expected Q2 2022.","VYN201 preclinical data demonstrated efficacy in rheumatoid arthritis and vitiligo models vs active controls.","Entered $30M equity purchase agreement with Lincoln Park Capital over 36 months."],"consensus_eps_estimate":null,"consensus_eps_actual":0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":178000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371233,"accession_number":"0001104659-22-043670","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2022-04-07T23:59:59+00:00","items":["4.01","8.01","9.01"],"status":"ready","headline":"VYNE reports positive Phase 1b data for FMX114 in atopic dermatitis; appoints Baker Tilly as auditor after PwC dismissal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FMX114 showed statistically significant reduction in ADSI score at week 2: -81.4% mean reduction vs -54.3% for vehicle (p=0.004).","Pruritus reduced 96.4% mean from baseline for FMX114 vs 45.8% for vehicle at week 2.","Phase 2a safety and efficacy results expected in Q2 2022.","Audit committee dismissed PwC as auditor effective April 6, 2022; appointed Baker Tilly US, LLP as new auditor.","PwC's 2021 report included going concern explanatory paragraph due to incurred losses and negative cash flows."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390238,"accession_number":"0001104659-22-039716","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2022-03-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"VYNE reports positive preclinical RA data for pan-BET inhibitor VYN201; on track for H2 2022 Ph1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VYN201 intra-articular injection showed statistically significant inhibition of paw thickening at 1 and 10 mg/kg (p<0.01).","At 1 mg/kg, paw thickness reduced 26.8% vs untreated; at 10 mg/kg, reduced 37.6%.","Arthritis scores at 1 and 10 mg/kg were near normal (0.57 and 0.67), reductions of 76.5% and 79.9%.","VYN201 numerically superior to intra-articular dexamethasone in both endpoints.","Company confirms timeline to initiate first-in-human trial for VYN201 in second half of 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390237,"accession_number":"0001104659-22-034768","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2022-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VYNE Therapeutics reports FY2021 revenue $14.8M, net loss $73.3M; pipeline progress","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2021 revenue $14.8M (down 30% YoY); net loss $73.3M, adjusted net loss $65.2M; EPS -$1.42.","FMX114 Phase 1b showed acceptable safety/PK; Phase 2a top-line results expected Q2 2022.","VYN201 preclinical data in TH17, fibrosis, vitiligo models show significant improvement; IND/H2 2022.","Divested MST franchise to Journey Medical for $20M upfront + $5M in 1 yr + up to $450M milestones.","Prepaid $35M debt in Aug 2021; entered $30M equity purchase agreement with Lincoln Park Capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390236,"accession_number":"0001104659-22-033991","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2022-03-15T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"VYNE Therapeutics enters $30M equity line with Lincoln Park Capital; names Tyler Zeronda CFO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $30M of common stock can be sold to Lincoln Park over 36 months; 1,667,593 commitment shares issued.","Regular purchases up to 200,000 shares/day (increased to 400,000 if closing price >= $1.00); pricing at discount to market.","Exchange cap of 11,227,637 shares (19.99% of outstanding) unless stockholder approval or avg price >= $0.545.","Tyler Zeronda appointed CFO and Treasurer effective March 14, 2022; annual base salary $340,000 with 40% target bonus.","Proceeds from equity line expected to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-03-15T23:59:59+00:00|390236"}